Vaxart Statistics
Total Valuation
Vaxart has a market cap or net worth of $84.30 million. The enterprise value is $77.05 million.
Important Dates
The last earnings date was Wednesday, August 13, 2025, after market close.
Earnings Date | Aug 13, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Vaxart has 228.22 million shares outstanding. The number of shares has increased by 38.50% in one year.
Current Share Class | 228.22M |
Shares Outstanding | 228.22M |
Shares Change (YoY) | +38.50% |
Shares Change (QoQ) | +0.19% |
Owned by Insiders (%) | 0.88% |
Owned by Institutions (%) | 11.89% |
Float | 226.21M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 1.04 |
Forward PS | 117.45 |
PB Ratio | 2.57 |
P/TBV Ratio | 3.35 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 0.95 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.60, with a Debt / Equity ratio of 0.58.
Current Ratio | 0.60 |
Quick Ratio | 0.57 |
Debt / Equity | 0.58 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -17.22 |
Financial Efficiency
Return on equity (ROE) is -100.35% and return on invested capital (ROIC) is -44.75%.
Return on Equity (ROE) | -100.35% |
Return on Assets (ROA) | -24.97% |
Return on Invested Capital (ROIC) | -44.75% |
Return on Capital Employed (ROCE) | -120.12% |
Revenue Per Employee | $768,800 |
Profits Per Employee | -$539,448 |
Employee Count | 105 |
Asset Turnover | 0.58 |
Inventory Turnover | n/a |
Taxes
In the past 12 months, Vaxart has paid $309,000 in taxes.
Income Tax | 309,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.80% in the last 52 weeks. The beta is 1.13, so Vaxart's price volatility has been higher than the market average.
Beta (5Y) | 1.13 |
52-Week Price Change | -36.80% |
50-Day Moving Average | 0.44 |
200-Day Moving Average | 0.54 |
Relative Strength Index (RSI) | 44.15 |
Average Volume (20 Days) | 912,212 |
Short Selling Information
The latest short interest is 21.17 million, so 9.28% of the outstanding shares have been sold short.
Short Interest | 21.17M |
Short Previous Month | 14.68M |
Short % of Shares Out | 9.28% |
Short % of Float | 9.36% |
Short Ratio (days to cover) | 2.61 |
Income Statement
In the last 12 months, Vaxart had revenue of $80.72 million and -$56.64 million in losses. Loss per share was -$0.25.
Revenue | 80.72M |
Gross Profit | -37.48M |
Operating Income | -55.51M |
Pretax Income | -75.38M |
Net Income | -56.64M |
EBITDA | -46.60M |
EBIT | -55.51M |
Loss Per Share | -$0.25 |
Full Income Statement Balance Sheet
The company has $26.27 million in cash and $19.02 million in debt, giving a net cash position of $7.25 million or $0.03 per share.
Cash & Cash Equivalents | 26.27M |
Total Debt | 19.02M |
Net Cash | 7.25M |
Net Cash Per Share | $0.03 |
Equity (Book Value) | 32.88M |
Book Value Per Share | 0.14 |
Working Capital | -47.50M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$37.09 million and capital expenditures -$80,000, giving a free cash flow of -$37.17 million.
Operating Cash Flow | -37.09M |
Capital Expenditures | -80,000 |
Free Cash Flow | -37.17M |
FCF Per Share | -$0.16 |
Full Cash Flow Statement Margins
Gross margin is -46.42%, with operating and profit margins of -68.76% and -70.17%.
Gross Margin | -46.42% |
Operating Margin | -68.76% |
Pretax Margin | -69.78% |
Profit Margin | -70.17% |
EBITDA Margin | -57.73% |
EBIT Margin | -68.76% |
FCF Margin | n/a |
Dividends & Yields
Vaxart does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -38.50% |
Shareholder Yield | -38.50% |
Earnings Yield | -67.19% |
FCF Yield | -44.09% |
Dividend Details Analyst Forecast
The average price target for Vaxart is $3.00, which is 712.13% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $3.00 |
Price Target Difference | 712.13% |
Analyst Consensus | Strong Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | 36.24% |
EPS Growth Forecast (5Y) | 0.02% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 4 |